Sign in

You're signed outSign in or to get full access.

Shashank Krishnakumar

Shashank Krishnakumar

Senior Research Analyst specializing in pharmaceutical equity research at Emkay Global

Mumbai, MH, IN

Shashank Krishnakumar is a Senior Research Analyst specializing in pharmaceutical equity research at Emkay Global Financial Services, focusing on major companies such as Cipla and Sun Pharma. He regularly participates in high-profile earnings calls, providing in-depth coverage and market insights for India's leading pharma firms, though public sources do not reveal specific performance statistics or TipRanks rankings. Krishnakumar began his current role at Emkay Global in 2024 and is registered under SEBI's Research Analyst Regulations, 2014. His professional background highlights expertise in pharma sector trends, and he is recognized for his sectoral knowledge within India's financial services industry.

Shashank Krishnakumar's questions to DR REDDYS LABORATORIES (RDY) leadership

Question · Q3 2026

Shashank Krishnakumar inquired about the on-site verification requested by the SEC for Semaglutide tablets filing in India, asking if it would meaningfully impact approval timelines and if there is any litigation overhang for the tablets launch post-March.

Answer

CEO Erez Israeli expressed no concerns regarding the on-site verification for Semaglutide tablets, implying it would not significantly impact approval timelines. He also confirmed that there is no litigation overhang for the tablets launch in India post-March.

Ask follow-up questions

Fintool

Fintool can predict DR REDDYS LABORATORIES logo RDY's earnings beat/miss a week before the call

Question · Q3 2026

Shashank Krishnakumar inquired about the potential impact of an on-site verification request from the SEC on the approval timelines for Semaglutide tablets in India and confirmed the absence of litigation overhang post-March launch.

Answer

CEO Erez Israeli expressed no concerns regarding the on-site verification for Semaglutide tablets in India, indicating it would not meaningfully impact approval timelines. He also confirmed that there is no litigation overhang for the launch of the tablets in India post-March.

Ask follow-up questions

Fintool

Fintool can write a report on DR REDDYS LABORATORIES logo RDY's next earnings in your company's style and formatting

Question · Q1 2026

Shashank Krishnakumar of Emkay Global Financial Services Ltd asked for the value of the out-licensing income booked in the quarter and questioned how the company could maintain its pace of complex generic launches while moderating R&D spend.

Answer

CFO M V Narasimham quantified the out-licensing income at ₹120 crores, noting it's a recurring part of the business. CEO Erez Israeli explained that current R&D spending impacts products 10-12 years in the future, so moderating it now does not affect the launch pipeline for the immediate term, as those products are already developed or filed.

Ask follow-up questions

Fintool

Fintool can auto-update your Excel models when DR REDDYS LABORATORIES logo RDY reports

Question · Q4 2025

Shashank Krishnakumar asked if Dr. Reddy's anticipates any meaningful benefit from the import alert issued to a competitor's facility for Revlimid, given the volume restrictions in place.

Answer

CEO Erez Israeli stated concisely that he does not believe the competitor's import alert will have any impact on Dr. Reddy's.

Ask follow-up questions

Fintool

Fintool can alert you when DR REDDYS LABORATORIES logo RDY beats or misses